2024-10-07 - Analysis Report
## Gilead Sciences Inc. (GILD) Stock Analysis

**Company Overview:** Gilead Sciences Inc. is a biopharmaceutical company that researches, develops, and commercializes medicines for the treatment of life-threatening diseases. 

**Performance Analysis:**

**1. Performance vs. S&P 500:**

GILD's cumulative return of -12.26% significantly lags behind the S&P 500 (VOO) return of 133.14%. The current relative divergence of -145.4 represents GILD's underperformance compared to the market, placing it at the 6.43% position within the historical range of its relative divergence.

**2. Recent Price Fluctuations:**

* **Closing Price:** $84.59
* **5-day Moving Average:** $84.26
* **20-day Moving Average:** $83.22
* **60-day Moving Average:** $77.96

The stock price currently sits above all three moving averages, suggesting potential upward momentum.

**3. Technical Indicators:**

* **RSI:** 59.2 (Neutral)
* **PPO:** -0.24 (Weak Momentum)
* **Delta_Previous_Relative_Divergence:** -4.28 (Short-term Downtrend)
* **Expected_Return:** 0.0% (5-year expected return over S&P 500)

GILD's RSI indicates a neutral level of momentum, while its PPO suggests a weak momentum. The negative Delta_Previous_Relative_Divergence signals a short-term downtrend. The expected return of 0.0% suggests that GILD is not expected to outperform the S&P 500 in the next 5 years.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-08 | 1.29 | 6.95 B$ |
| 2024-05-08 | -3.34 | 6.69 B$ |
| 2023-11-07 | 1.75 | 7.05 B$ |
| 2023-08-04 | 0.84 | 6.60 B$ |
| 2024-08-08 | 0.84 | 6.60 B$ |

Gilead's latest earnings for Q2 2024 show a positive EPS of $1.29, beating analyst estimates of $1.04. The company's revenue also came in above expectations, reaching $6.95 billion. The earnings report was a positive sign for the company, as it demonstrated continued growth despite a challenging economic environment.

**5. Recent News and Issues:**

* **Market Outlook:** According to FINBOLD, analysts remain optimistic about Gilead's long-term growth potential, citing its strong portfolio of HIV and HCV treatments, and promising pipeline of new therapies. 
* **Analyst Opinions:**  Many analysts see GILD as a value stock with potential for upside. The company's recent earnings beat has boosted investor confidence.
* **Performance Highlights:** Gilead's HIV and HCV treatments continue to be top performers, driving a large portion of the company's revenue. 

**6. Overall Analysis:**

Gilead Sciences Inc. (GILD) is a biopharmaceutical company with a strong track record in the HIV and HCV treatment market. While its recent performance has lagged behind the S&P 500, the company is showing signs of growth and is expected to benefit from its robust pipeline. 

**Key takeaways:**

* GILD has underperformed the market significantly in recent years.
* The company's latest earnings report shows positive signs of growth and beats expectations.
* Analysts remain optimistic about GILD's long-term growth potential.
* The stock price is currently showing signs of upward momentum.

**Conclusion:**

Overall, Gilead Sciences Inc. presents a potentially attractive investment opportunity for long-term investors seeking exposure to the biopharmaceutical industry. However, investors should carefully consider the company's performance relative to the market, and its expected return before making any investment decisions. 
